Variants of CDKAL1 rs7754840 (G/C) and CDKN2A/2B rs10811661 (C/T) with gestational diabetes: insignificant association

Abstract Objectives Pathophysiological similarity exists between gestational diabetes mellitus (GDM) and type 2 diabetes mellitus with common genetic origin. Genetic liability for GDM in our population is still not researched. The goal was to reveal the genotypic and allele frequency differences of 2 single nucleotide polymorphisms (SNPs) namely, CDKAL1 (rs7754840) and CDKN2A/2B (rs10811661) between GDM pregnancies and normal pregnancies. We assessed them by real time polymerase chain reaction using Taqman® allelic discrimination assays. We included 47 GDM pregnant subjects and 51 normal glucose tolerance (NGT) pregnant women as controls. Results The genotype frequencies in the GDM group and the NGT group of rs7754840-GG/GC/CC were 6.4/15.7% (3/8), 55.3/45.1% (26/23) and 38.3/39.2% (18/20) respectively. Also, those of rs10811661-CC/CT/TT were 74.5/14.9/4.3% (38/7/2) and 80.9/19.6/5.9% (38/10/3) respectively. The allele frequencies in the GDM group and the NGT group of C/G and T/C were 66/34% (62/32), 61.8/38.2% (63/39) and 11.7/88.3% (11/83), 15.7/84.3% (16/86) respectively. There were no statistical differences between the two groups in allele frequencies and genotype frequencies (all P > 0.05). Non-significant association was seen in the two SNPs of CDKAL1 and CDKN2A/B genes with GDM. Further studies are essential to validate data

Molecular detection of CFFDNA for early laboratory diagnosis of X linked disorders carriers

Enhancement of DNA detection assays increase the use of non-invasive prenatal diagnosis that is consequently enhances the supervision plan of pregnant woman with genetic disorder expected babies. Aim of work: Current work was planed to examine plasma of pregnant women starting from 6th week pregnancy for Cell-free fetal DNA, to determine embryonic sex type with consequent prospect of detection of fetal anomalies such as aneuploidies. Method: Samples collected from 6th week till 11th week of pregnancy according to pregnancy age and tested using Real time PCR for determination of fetal sex. Results: Testing of samples resulted in detection of fetal sex starting from 6th week and the later the gestational age the better the result for detection of fetal sex, all results were confirmed by Ultrasound scan and neonatal outcome. Testing results revealed PCR detection for 58 males and 92 females with confusion in one fetus due to non identical twins

Light Emitting Diodes and Low Level Laser Light Therapy

Low level laser therapy (LLLT), including coherent and non-coherent light sources, also known as photobiomodulation, is a non-ablative treatment modality that alters cellular biochemical processes through its action on the mitochondria and by changing the cellular redox state. Treatment is delivered by exposing cells or tissue to light of low energy densities for a specific amount of time. This process has been reported to have beneficial therapeutic effects on a wide variety of conditions that benefit from alleviation of pain or inflammation, immunomodulation, and promotion of wound healing and tissue regeneration. LLLT’s use in dermatology is still considered experimental and investigational, hence it is currently used primarily as an adjunct therapy. Skepticisms mostly stem from ambiguities in its mechanism of action and the complexity of its dosimetry. For the same reasons, guidelines directing its use are not yet well established. Nonetheless, many recent studies have reported favorable outcomes achieved with LLLT in a number of indications (e.g. wound healing, hair growth, skin rejuvenation, fibrosis) with minimal adverse events